Literature DB >> 708018

Pharmacokinetics of netilmicin in patients with renal impairment and in patients on dialysis.

F C Luft, D R Brannon, L L Stropes, R J Costello, R S Sloan, D R Maxwell.   

Abstract

The pharmacokinetics of netilmicin were examined in 25 adult subjects, 7 normal subjects, and 18 patients with renal impairment. Five were dialysis patients who were studied on and off dialysis. Netilmicin, 2 mg/kg, was infused intravenously over 1 h. The peak serum concentration ranged from 9 to 11 mug/ml. The mean biological half-life of netilmicin for subjects with a creatinine clearance (Ccr) > 70 ml/min was 2.7 h, for those with Ccr > 25 < 70 ml/min it was 10 h, for those with Ccr > 4 < 25 ml/min it was 32 h, and for those who were anephric it was 42 h. Ccr was correlated positively with the elimination constant and the drug's serum clearance. It was negatively correlated with the drug's volume of distribution. The dialyzer clearance of netilmicin was positively correlated with plasma flow rate and was similar to values previously reported for gentamicin. Netilmicin behaves in a fashion similar to other aminoglycosides. Therapeutic guidelines are suggested.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 708018      PMCID: PMC352472          DOI: 10.1128/AAC.14.3.403

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  17 in total

1.  Pharmacokinetics of amikacin in patients with normal or impaired renal function: radioenzymatic acetylation assay.

Authors:  J Plantier; A W Forrey; M A O'Neill; A D Blair; T G Christopher; R E Cutler
Journal:  J Infect Dis       Date:  1976-11       Impact factor: 5.226

2.  Gentamicin concentrations in blood, urine, and renal tissue of patients with end-stage renal disease.

Authors:  W M Bennett; M N Hartnett; R Craven; D N Gilbert; G A Porter
Journal:  J Lab Clin Med       Date:  1977-08

3.  Clearance of gentamicin during hemodialysis: comparison of four artificial kidneys.

Authors:  B A Halpren; S G Axline; N S Coplon; D M Brown
Journal:  J Infect Dis       Date:  1976-06       Impact factor: 5.226

4.  Netilmicin pharmacokinetics after single intravenous doses to elderly male patients.

Authors:  P G Welling; A Baumueller; C C Lau; P O Madsen
Journal:  Antimicrob Agents Chemother       Date:  1977-09       Impact factor: 5.191

5.  Evaluation of the mass-transfer process in artificial kidneys.

Authors:  J M Kooijman
Journal:  Neth J Med       Date:  1973       Impact factor: 1.422

6.  Biological activity of netilmicin, a broad-spectrum semisynthetic aminoglycoside antibiotic.

Authors:  G H Miller; G Arcieri; M J Weinstein; J A Waitz
Journal:  Antimicrob Agents Chemother       Date:  1976-11       Impact factor: 5.191

7.  Comparative nephrotoxicities of netilmicin and gentamicin in rats.

Authors:  F C Luft; M N Yum; S A Kleit
Journal:  Antimicrob Agents Chemother       Date:  1976-11       Impact factor: 5.191

8.  Antimicrobial activity in vitro of netilmicin and comparison with sisomicin, gentamicin, and tobramycin.

Authors:  B R Meyers; S Z Hirschman
Journal:  Antimicrob Agents Chemother       Date:  1977-01       Impact factor: 5.191

9.  Clinical pharmacokinetics of sisomicin: dosage schedules in renal-impaired patients.

Authors:  J C Pechère; M M Pechère; R Dugal
Journal:  Antimicrob Agents Chemother       Date:  1976-05       Impact factor: 5.191

10.  Accumulation pharmacokinetics of tobramycin.

Authors:  J J Schentag; G Lasezkay; T J Cumbo; M E Plaut; W J Jusko
Journal:  Antimicrob Agents Chemother       Date:  1978-04       Impact factor: 5.191

View more
  12 in total

Review 1.  Drug therapy in patients undergoing continuous ambulatory peritoneal dialysis. Clinical pharmacokinetic considerations.

Authors:  E Keller; P Reetze; P Schollmeyer
Journal:  Clin Pharmacokinet       Date:  1990-02       Impact factor: 6.447

Review 2.  Clinical pharmacokinetics of aminoglycoside antibiotics.

Authors:  J C Pechere; R Dugal
Journal:  Clin Pharmacokinet       Date:  1979 May-Jun       Impact factor: 6.447

3.  Prospective comparative study of efficacy and toxicity of netilmicin and amikacin.

Authors:  B V Bock; P H Edelstein; R D Meyer
Journal:  Antimicrob Agents Chemother       Date:  1980-02       Impact factor: 5.191

4.  Predicted tissue accumulation of netilmicin in patients.

Authors:  D J Edwards; A Mangione; T J Cumbo; J J Schentag
Journal:  Antimicrob Agents Chemother       Date:  1981-12       Impact factor: 5.191

5.  Comparison of four renal function estimation equations for pharmacokinetic modeling of gentamicin in geriatric patients.

Authors:  Nicolas Charhon; Michael N Neely; Laurent Bourguignon; Pascal Maire; Roger W Jelliffe; Sylvain Goutelle
Journal:  Antimicrob Agents Chemother       Date:  2012-01-30       Impact factor: 5.191

Review 6.  Clinical pharmacokinetics of antibiotics in patients with impaired renal function.

Authors:  W L St Peter; K A Redic-Kill; C E Halstenson
Journal:  Clin Pharmacokinet       Date:  1992-03       Impact factor: 6.447

Review 7.  Nonparametric meta-analysis of published data on kidney-function dependence of pharmacokinetic parameters for the aminoglycoside netilmicin.

Authors:  F Keller; K Erdmann; M Giehl; P Buettner
Journal:  Clin Pharmacokinet       Date:  1993-07       Impact factor: 6.447

8.  Isepamicin disposition in subjects with various degrees of renal function.

Authors:  C E Halstenson; J S Kelloway; M B Affrime; C C Lin; M A Teal; B E Shapiro; W M Awni
Journal:  Antimicrob Agents Chemother       Date:  1991-11       Impact factor: 5.191

9.  Population pharmacokinetics of netilmicin in short-term prophylactic treatment.

Authors:  Nerea Jauregizar; Jeff A Wald; Ander Astobieta; Jose M Rodriguez Sasiain; John C Lukas; Rosario Calvo
Journal:  Br J Clin Pharmacol       Date:  2003-06       Impact factor: 4.335

Review 10.  Netilmicin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  D M Campoli-Richards; S Chaplin; R H Sayce; K L Goa
Journal:  Drugs       Date:  1989-11       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.